- Drug device combination products, integrating medical devices with pharmaceutical or biologic components, are becoming critical to modern healthcare delivery across therapeutic areas due to their improved treatment efficacy, targeted delivery, and enhanced patient adherence
- The accelerating demand for combination products is primarily fueled by the rising burden of chronic diseases, the shift toward self-administration therapies, and the growing need for precision medicine in managing complex conditions
- North America dominated the drug device combination market with the largest revenue share of 41.36% in 2024, characterized by mature regulatory framework, advanced healthcare infrastructure, and the strong presence of leading pharmaceutical and medtech companies investing heavily in innovation, particularly in areas such as insulin delivery systems, prefilled syringes, and drug-eluting stents
- Asia-Pacific is expected to be the fastest growing region in the drug device combination market during the forecast period due to increasing healthcare expenditure, expanding access to medical devices, and rising awareness of advanced treatment modalities
- Transdermal patches segment dominated the drug device combination market with a market share of 23.6% in 2024, driven by its non-invasive drug delivery, sustained release capabilities, and improved patient compliance for chronic conditions such as pain and hormone therapy
